Glycoimmunomics of human cancer: current concepts and future perspectives (Q36768301)

16 August 2017

1 reference

title

Glycoimmunomics of human cancer: current concepts and future perspectives (English)

1 reference

16 August 2017

4

Donald L Morton

1 reference

16 August 2017

Mepur H Ravindranath

1

1 reference

16 August 2017

Paul Yesowitch

series ordinal

2

1 reference

16 August 2017

Cindy Sumobay

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

16 August 2017

1 reference

16 August 2017

3

1 reference

16 August 2017

2

1 reference

16 August 2017

201-214

1 reference

Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma

16 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Melanoma, a tumor based on a mutant stem cell?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Significance, detection and markers of disseminated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Immunotherapy with ligands of natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

T-cell recognition of glycolipids presented by CD1 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

CD1d ligands: the good, the bad, and the ugly

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Structure, biosynthesis and functions of glycoprotein glycans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

The molecular and cell biology of glycosyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

T cell-independent antigens type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

On the structure of polymeric IgM.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

The biological effects of IgM hexamer formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

J chain synthesis and secretion of hexameric IgM is differentially regulated by lipopolysaccharide and interleukin 5

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Augmentation of natural antiganglioside IgM antibodies in lower motor neuron disease (LMND) and role of CD5+ B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Factors affecting the fine specificity and sensitivity of serum antiganglioside antibodies in ELISA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Human antiganglioside autoantibodies: validation of ELISA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Demonstration of serum precipitin to brain ganglioside.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

THE PRODUCTION OF ANTISERA TO GANGLIOSIDES FROM HUMAN NERVOUS TISSUE

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Immunogenicity of membrane-bound gangliosides in viable whole-cell vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Immunosuppression by human gangliosides. II. Carbohydrate structure and inhibition of human NK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Sialylated lactosylceramides. Possible inducers of non-specific immunosuppression and atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Gangliosides and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Interleukin-2 binds to ganglioside GD(1b).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Gangliosides GD1b, GT1b, and GQ1b enhance IL-2 and IFN-gamma production and suppress IL-4 and IL-5 production in phytohemagglutinin-stimulated human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Degradation of NF-kappa B in T cells by gangliosides expressed on renal cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Serum total ganglioside level correlates with clinical course in melanoma patients after immunotherapy with therapeutic cancer vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Gangliosides of organ-confined versus metastatic androgen-receptor-negative prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Endogenous immune response to gangliosides in patients with confined prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

Immunogenic gangliosides in human ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.3.2.201

21 January 2018

Identifiers

DOI

10.2217/14796694.3.2.201

1 reference

16 August 2017

1 reference